🚀 VC round data is live in beta, check it out!
Reig Jofré Valuation Multiples
Discover revenue and EBITDA valuation multiples for Reig Jofré and similar public comparables like Oryzon Genomics, Adagene, Arcturus Therapeutics, Binex and more.
Reig Jofré Overview
About Reig Jofré
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
Founded
1993
HQ
Employees
794
Website
Sectors
Financials (LTM)
EV
$347M
Reig Jofré Financials
Reig Jofré reported last 12-month revenue of $398M and EBITDA of $35M.
In the same LTM period, Reig Jofré generated $238M in gross profit, $35M in EBITDA, and $6M in net income.
Revenue (LTM)
Reig Jofré P&L
In the most recent fiscal year, Reig Jofré reported revenue of $389M and EBITDA of $38M.
Reig Jofré expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $398M | XXX | $389M | XXX | XXX | XXX |
| Gross Profit | $238M | XXX | $230M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $35M | XXX | $38M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $6M | XXX | $6M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $70M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Reig Jofré Stock Performance
Reig Jofré has current market cap of $259M, and enterprise value of $347M.
Market Cap Evolution
Reig Jofré's stock price is $3.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $347M | $259M | -0.3% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialReig Jofré Valuation Multiples
Reig Jofré trades at 0.9x EV/Revenue multiple, and 9.8x EV/EBITDA.
EV / Revenue (LTM)
Reig Jofré Financial Valuation Multiples
As of April 21, 2026, Reig Jofré has market cap of $259M and EV of $347M.
Equity research analysts estimate Reig Jofré's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Reig Jofré has a P/E ratio of 45.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $259M | XXX | $259M | XXX | XXX | XXX |
| EV (current) | $347M | XXX | $347M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBIT | 34.9x | XXX | 41.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| P/E | 45.3x | XXX | 43.9x | XXX | XXX | XXX |
| EV/FCF | 274.0x | XXX | (326.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Reig Jofré Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Reig Jofré Margins & Growth Rates
Reig Jofré's revenue in the last 12 month grew by 9%.
Reig Jofré's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Reig Jofré's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Reig Jofré's rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Reig Jofré Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Reig Jofré Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Reig Jofré | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adagene | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcturus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| Voyager Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Reig Jofré M&A Activity
Reig Jofré acquired XXX companies to date.
Last acquisition by Reig Jofré was on XXXXXXXX, XXXXX. Reig Jofré acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Reig Jofré
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialReig Jofré Investment Activity
Reig Jofré invested in XXX companies to date.
Reig Jofré made its latest investment on XXXXXXXX, XXXXX. Reig Jofré invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Reig Jofré
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Reig Jofré
| When was Reig Jofré founded? | Reig Jofré was founded in 1993. |
| Where is Reig Jofré headquartered? | Reig Jofré is headquartered in Spain. |
| How many employees does Reig Jofré have? | As of today, Reig Jofré has over 794 employees. |
| Is Reig Jofré publicly listed? | Yes, Reig Jofré is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Reig Jofré? | Reig Jofré trades under RJF ticker. |
| When did Reig Jofré go public? | Reig Jofré went public in 2006. |
| Who are competitors of Reig Jofré? | Reig Jofré main competitors are Oryzon Genomics, Adagene, Arcturus Therapeutics, Binex. |
| What is the current market cap of Reig Jofré? | Reig Jofré's current market cap is $259M. |
| What is the current revenue of Reig Jofré? | Reig Jofré's last 12 months revenue is $398M. |
| What is the current revenue growth of Reig Jofré? | Reig Jofré revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Reig Jofré? | Current revenue multiple of Reig Jofré is 0.9x. |
| Is Reig Jofré profitable? | Yes, Reig Jofré is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Reig Jofré? | Reig Jofré's last 12 months EBITDA is $35M. |
| What is Reig Jofré's EBITDA margin? | Reig Jofré's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Reig Jofré? | Current EBITDA multiple of Reig Jofré is 9.8x. |
| What is the current FCF of Reig Jofré? | Reig Jofré's last 12 months FCF is $1M. |
| What is Reig Jofré's FCF margin? | Reig Jofré's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Reig Jofré? | Current FCF multiple of Reig Jofré is 274.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.